Skip to main content
SpringerLink
Log in

Cardioprotective properties of the platelet P2Y12 receptor inhibitor prasugrel on cardiac ischemia/reperfusion injury

  • Article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Objective

The effects of prasugrel, a third-generation thienopyridine, on myocardial infarction, and ischemia-induced ventricular arrhythmias was evaluated in open-chest anesthetized rats. The role of protein kinase C and phosphoinositide 3-kinase pathways in these effects was also examined.

Methods

The effect of P2Y12 receptor inhibition by prasugrel (3–10 mg/kg, po) on infarct size after 30-min coronary artery occlusion and 120-min reperfusion or on arrhythmias after 7-min coronary occlusion and 7-min reperfusion was evaluated.

Results

In the control group, 31.25 ± 3.01% of the risk zone infarcted. At both prasugrel doses, infarct size was significantly smaller than that in the control group: 5.03 ± 0.81% for 3 mg/kg (p < 0.0001), and 8.78 ± 2.04% for 10 mg/kg (p < 0.0001). The protein kinase C antagonist chelerythrine abolished the anti-infarct effect of prasugrel at 24.77 ± 1.73% as did the phosphoinositide 3-kinase antagonist wortmannin abolished the anti-infarct effect of prasugrel at 27.45 ± 2.74%. Ten mg/kg prasugrel reduced the duration of VT (p = 0.0152 vs control), and wortmannin, but not chelerythrine, reversed the effect of prasugrel on arrhythmias (p = 0.0295).

Conclusion

The selective P2Y12 inhibitor prasugrel provides effective protection against myocardial infarction and ischemia-induced ventricular arrhythmias in rats. As in ischemic postconditioning, protein kinase C and phosphoinositide 3-kinase signaling pathways play a role in this protection.

Graphic abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lecour S, Botker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, et al. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014;104:399–411.

    Article  CAS  Google Scholar 

  2. Sugidachi A, Yamaguchi S, Jakubowski JA, Ohno K, Tomizawa A, Hashimoto M, et al. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats. J Cardiovasc Pharmacol. 2011;58:329–34.

    Article  CAS  Google Scholar 

  3. Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18:251–62.

    Article  CAS  Google Scholar 

  4. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448–60.

    Article  CAS  Google Scholar 

  5. Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013;27:403–12.

    Article  CAS  Google Scholar 

  6. Yeung J, Apopa PL, Vesci J, Kenyon V, Rai G, Jadhav A, et al. Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation. Mol Pharmacol. 2012;81:420–30.

    Article  CAS  Google Scholar 

  7. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229–317.

    Article  CAS  Google Scholar 

  8. Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Leon C, Cazenave JP, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin–a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 2001;505:281–90.

    Article  CAS  Google Scholar 

  9. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078–85.

    Article  CAS  Google Scholar 

  10. Birnbaum Y, Birnbaum GD, Birnbaum I, Nylander S, Ye Y. Ticagrelor and rosuvastatin have additive cardioprotective effects via adenosine. Cardiovasc Drugs Ther. 2016;30:539–50.

    Article  CAS  Google Scholar 

  11. Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol. 2012;11:67.

    Article  Google Scholar 

  12. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010;122:394–403.

    Article  Google Scholar 

  13. Ogawa T, Hashimoto M, Niitsu Y, Jakubowski JA, Tani Y, Otsuguro K, et al. Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. Eur J Pharmacol. 2009;612:29–34.

    Article  CAS  Google Scholar 

  14. Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy. 2009;29:1089–102.

    Article  CAS  Google Scholar 

  15. Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H. Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicol. 2006;25:499–521.

    Article  CAS  Google Scholar 

  16. Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol. 2006;2:715–31.

    Article  CAS  Google Scholar 

  17. Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, et al. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther. 2013;139:213–48.

    Article  CAS  Google Scholar 

  18. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988;22:447–55.

    Article  CAS  Google Scholar 

  19. Winter MP, Kozinski M, Kubica J, Aradi D, Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej. 2015;11(4):259–80.

    PubMed  PubMed Central  Google Scholar 

  20. Iliodromitis EK, Cohen MV, Dagres N, Andreadou I, Kremastinos DT, Downey JM. What is wrong with cardiac conditioning? We may be shooting at moving targets. J Cardiovasc Pharmacol Ther. 2015;20:357–69.

    Article  Google Scholar 

  21. Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition—comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016;173:1163–78.

    Article  CAS  Google Scholar 

  22. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci. 2010;67:499–511.

    Article  CAS  Google Scholar 

  23. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264–74.

    Article  CAS  Google Scholar 

  24. Suh DH, Trinh HK, Liu JN, le Pham D, Park SM, Park HS, et al. P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma. J Cell Mol Med. 2016;20:333–41.

    Article  CAS  Google Scholar 

  25. Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T, et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock. 2011;35:289–92.

    Article  CAS  Google Scholar 

  26. Do Carmo H, Arjun S, Petrucci O, Yellon DM, Davidson SM. The caspase 1 inhibitor VX-765 protects the isolated rat heart via the RISK pathway. Cardiovasc Drugs Ther. 2018;32:165–8.

    Article  CAS  Google Scholar 

  27. Liverani E, Rico MC, Garcia AE, Kilpatrick LE, Kunapuli SP. Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Ther. 2013;344:231–43.

    Article  CAS  Google Scholar 

  28. Bell RM, Sivaraman V, Kunuthur SP, Cohen MV, Downey JM, Yellon DM. Cardioprotective properties of the platelet P2Y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood. Cardiovasc Drugs Ther. 2015;29:415–8.

    Article  CAS  Google Scholar 

  29. Cohen MV, Yang XM, White J, Yellon DM, Bell RM, Downey JM. Cangrelor-mediated cardioprotection requires platelets and sphingosine phosphorylation. Cardiovasc Drugs Ther. 2016;30:229–32.

    Article  CAS  Google Scholar 

  30. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res. 2008;79:134–40.

    Article  CAS  Google Scholar 

  31. Wang C, Zhao G, Wang X, Nie S. Effect of potent P2Y12 inhibitors on ventricular arrhythmias and cardiac dysfunction in coronary artery disease: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:8572740.

    PubMed  PubMed Central  Google Scholar 

  32. Ni M, Ruan L, Zhang C. Antiarrhythmic peptide AAP10 prevents arrhythmias induced by protein kinase C activation in rabbit left ventricular wedges. Int Heart J. 2015;56:234–8.

    Article  CAS  Google Scholar 

  33. Zaid Y, Senhaji N, Darif Y, Kojok K, Oudghiri M, Naya A. Distinctive roles of PKC delta isozyme in platelet function. Curr Res Transl Med. 2016;64:135–9.

    Article  CAS  Google Scholar 

  34. Yang T, Meoli DF, Moslehi J, Roden DM. Inhibition of the alpha-subunit of phosphoinositide 3-kinase in heart increases late sodium current and is arrhythmogenic. J Pharmacol Exp Ther. 2018;365:460–6.

    Article  CAS  Google Scholar 

  35. Ravingerova T, Matejikova J, Pancza D, Kolar F. Reduced susceptibility to ischemia-induced arrhythmias in the preconditioned rat heart is independent of PI3-kinase/Akt. Physiol Res. 2009;58:443–7.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Scientific and Technological Research Council of Turkey (TUBITAK) 1002 program (Grant number: 216S328).

Funding

This work was supported by the Scientific and Technological Research Council of Turkey (TUBITAK) 1002 program (Grant number: 216S328).

Author information

Authors and Affiliations

  1. Department of Medical Pharmacology, Medical School, Aydin Adnan Menderes University, Aydin, 09100, Turkey

    Turhan Dost

Authors
  1. Turhan Dost
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Turhan Dost.

Ethics declarations

Conflict of interest

The author declares no conflicts of interests related to this study.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of laboratory animals were followed and approved by the Animal Care Committee of Aydin Adnan Menderes University, Turkey. No human studies were carried out for this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dost, T. Cardioprotective properties of the platelet P2Y12 receptor inhibitor prasugrel on cardiac ischemia/reperfusion injury. Pharmacol. Rep 72, 672–679 (2020). https://doi.org/10.1007/s43440-019-00046-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43440-019-00046-5

Keywords

Search

Navigation